Hereditary Hemorrhagic Telangiectasia Clinical Trial
OBJECTIVES:
I. Evaluate the efficacy of octreotide, a somatostatin octapeptide analog, in decreasing
gastrointestinal bleeding in patients with hormone-refractory hereditary hemorrhagic
telangiectasia or senile ectasia.
PROTOCOL OUTLINE: Patients are treated with subcutaneous injections of octreotide twice a
day. The dose is adjusted based on response.
If there is no requirement for transfusions or intravenous iron for 4 weeks and the
hemoglobin is greater than 10 mg/dL, therapy is continued for 1 year. If there is no
decrease in bleeding after 10 weeks, the patient is removed from study.
;
Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02874326 -
Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber
|
Phase 2 | |
Completed |
NCT00389935 -
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
|
Phase 2 | |
Active, not recruiting |
NCT04646356 -
Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 2 | |
Completed |
NCT04139018 -
Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia
|
Phase 2 | |
Completed |
NCT03691142 -
Evaluation of Obstetrical and Neonatal Complications in Hereditary Haemorrhagic Telangiectasia (HHT)
|
||
Recruiting |
NCT04404881 -
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
|
Phase 2 | |
Completed |
NCT02977637 -
MRA With Feraheme in HHT
|
Phase 1 | |
Completed |
NCT01485224 -
Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia
|
Phase 2 | |
Recruiting |
NCT06259292 -
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
|
||
Active, not recruiting |
NCT04150822 -
Hereditary Hemorrhagic Telangiectasia (HHT) Research Outcomes Registry
|
||
Recruiting |
NCT03850964 -
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
|
Phase 2/Phase 3 | |
Completed |
NCT05752253 -
Counseling Intervention in Hereditary Hemorrhagic Telangiectasia in the COVID Era.
|
N/A | |
Not yet recruiting |
NCT02458703 -
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction
|
N/A | |
Completed |
NCT01752049 -
Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
|
Phase 1/Phase 2 | |
Completed |
NCT00004649 -
Study of the Natural History and Genotype-Phenotype Correlations of Hereditary Hemorrhagic Telangiectasia Patients
|
N/A | |
Active, not recruiting |
NCT04874558 -
Ultra-low-dose Chest CT for HHT
|
||
Completed |
NCT01031992 -
Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 3 | |
Recruiting |
NCT05269849 -
Sirolimus for Nosebleeds in HHT
|
Phase 2 | |
Completed |
NCT03572556 -
Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)
|
||
Completed |
NCT04113187 -
Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients
|
Phase 3 |